Statistics from Altmetric.com
Recent international guidelines recommend the use of biosimilar biological drugs on similar terms as their corresponding originators, including switching from a bio-originator to the biosimilar.1 However, the comparative safety of biosimilars in patients with inflammatory joint diseases (IJD) in routine care is still debated.2 In a phase 3 randomised trial among patients with rheumatoid arthritis, biosimilar etanercept (SB4) had slightly more hepatobiliary adverse events compared with the originator (ETN), possibly explained by differences in patients’ comorbid diseases and comedication use.3 The occurrence of, for example, hepatobiliary safety events is likely to differ across indications (due to differences in age, body weight, use of methotrexate, comedication, etc) and has not been explored in etanercept-treated patients with psoriatic arthritis or axial spondyloarthritis.4
In April 2016, a mandatory switch from ETN to SB4 was performed in Denmark to save costs and the 1-year clinical …
Handling editor Josef S Smolen
HL and OH contributed equally.
Contributors BG and MLH contributed to the study design. BG, SG, MLH, MN, FM, NSK: data management, analyses of raw data and interpretation. All authors contributed to data collection and contributed to and approved the final manuscript.
Competing interests BG: AbbVie, Biogen, Pfizer, MSD. MLH: Orion, BMS, AbbVie, Biogen, Pfizer, MSD, Celltrion. AGL: AbbVie, MSD, Novartis, Pfizer, Roche, UCB. OH: AbbVie, Roche, Novartis. GE: Pfizer, Medac.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.